Abivax SA’s U.S.-listed ADS (ABVX) traded lower, down roughly 3% to about $116.55, in a move that looks driven more by positioning than by a fresh company-specific headline. With the stock still anchored to a single major near-term catalyst, modest drawdowns can occur when investors reduce exposure into the catalyst window or take profits after prior strength. (ir.abivax.com)

Abivax has said its pivotal Phase 3 ABTECT maintenance trial in moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026. That timeline has been reiterated in recent company materials, keeping attention tightly focused on the upcoming data as the next major valuation driver. (ir.abivax.com)

For clinical-stage biotech names, the weeks leading into a binary readout often bring volatility as investors rebalance risk, especially after large prior moves tied to earlier data. A 3% dip is consistent with routine “de-risking” or profit-taking while the market waits for the next definitive update from the Phase 3 maintenance study. (ir.abivax.com)

Abivax has indicated it expects to report first-quarter 2026 financial results on May 25, 2026, and it has also scheduled its annual general meeting for May 11, 2026. Those events can refresh investors on cash runway, operating burn, and trial progress, but the largest swing factor remains the late-Q2 2026 ABTECT-UC maintenance topline data. (ir.abivax.com)